About
Small Molecules for Oncology
Areas of Focus
Categories
Small Molecule PharmaceuticalSouthwestern U.S.
Clinical Trials (10)
View allTotal Trials
10
As Lead Sponsor
4
As Collaborator
6
Total Enrollment
531
By Phase
PHASE2: 8PHASE1: 2
By Status
WITHDRAWN: 3ACTIVE_NOT_RECRUITING: 3TERMINATED: 2RECRUITING: 1COMPLETED: 1
Clinical Trials Pipeline10 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
2032
2033
2034
2035
Today
Hover over trial bars to see details
Recent Trials
NCT04832438Lead Sponsor
9-ING-41 Plus Carboplatin in Patients With Advanced, Metastatic Salivary Gland Carcinoma
PHASE2Withdrawn
Started: Dec 18, 2030 · Completed: Jun 18, 2034
NCT06896188Collaborator
9-ING-41 Combined With Retifanlimab, Plus Modified FOLFIRINOX for Patients With Advanced Pancreatic Adenocarcinoma (RiLEY)
PHASE1Recruiting
12 participants
Started: Sep 22, 2025 · Completed: Dec 31, 2028
NCT05077800Collaborator
FOLFIRINOX + 9-Ing-41 + Losartan In Pancreatic Cancer
PHASE2Active, not recruiting
70 participants
Started: Mar 21, 2022 · Completed: Jul 31, 2026
NCT05116800Collaborator
Phase 2 Study of 9-ING-41 With Chemotherapy in Sarcoma
PHASE2Withdrawn
Started: Mar 1, 2022 · Completed: Aug 31, 2030
NCT05239182Collaborator
9-ING-41 Plus Retifanlimab and Gemcitabine/Nab-Paclitaxel in Patients With Advanced Pancreatic Adenocarcinoma
PHASE2Terminated
7 participants
Started: Jan 26, 2022 · Completed: Feb 4, 2024
Locations (1)
Headquarters
Fort Worth, TX, United States
Map
Loading map...